INDUSTRY SYMPOSIUM
Advanced NSCLCADCs
Best Practices in Managing Adverse Events with ADCs in NSCLC
18 min
Therapy Areas
Drug Classes
Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
All
FEATURED
ILCS
Webinars
Articles
Industry Sponsored
Featured Sessions
The Reading Room
Articles & Research
Aug
07
2026
ADCs
Advanced NSCLCBiomarkersADCs
EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel
G. Mountzios
Jul
20
2026
ADCs
Advanced NSCLCADCs
Sac-TMT plus pembrolizumab improves PFS in PD-L1-negative NSCLC
Jul
14
2026
ADCs
Advanced NSCLCADCs
Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date
M. HochmairG. MountziosA. AddeoM. Reck
Jul
14
2026
ADCs
Advanced NSCLCSCLCADCs
Antibody-drug conjugates across solid tumours: an ETOP/IBCSG expert group sets the research priorities
R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon
Industry Sponsored
Featured Sessions
The Reading Room
Articles & Research
Aug
07
2026
ADCs
Advanced NSCLCBiomarkersADCs
EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel
G. Mountzios
Jul
20
2026
ADCs
Advanced NSCLCADCs
Sac-TMT plus pembrolizumab improves PFS in PD-L1-negative NSCLC
Jul
14
2026
ADCs
Advanced NSCLCADCs
Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date
M. HochmairG. MountziosA. AddeoM. Reck
Jul
14
2026
ADCs
Advanced NSCLCSCLCADCs
Antibody-drug conjugates across solid tumours: an ETOP/IBCSG expert group sets the research priorities
R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon